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Although prostate cancer remains the most common male malig-
nant tumour in the Western world, there is still a lack of a suffi-
cient number of models for studying its development and
progression (Dijkman and Debruyne, 1996). The three human cell
lines, LNCaP, PC-3 and DU-145, all derived from metastatic
lesions from prostate cancer, are widely used (Stone et al, 1978;
Kaighn et al, 1979; Horoszewicz et al, 1983). Two of these three
cell lines are not representative of androgen receptor (AR) expres-
sion in prostate cancer in vivo (Hobisch et al, 1995). PC-3 and
DU-145 cells express very little or no AR, respectively, whereas
advanced prostate tumours and metastatic lesions from patients
who failed androgen ablation therapy were found to be altogether
AR-positive (Tilley et al, 1990; van der Kwast et al, 1991; Hobisch
et al, 1995; Taplin et al, 1995). On the other hand, LNCaP cells,
obtained from a lymph node metastasis of a patient who did not
respond to endocrine therapy, contain high levels of AR mRNA
and protein and are androgen-sensitive. The LNCaP AR, which
has a point mutation in the hormone-binding domain, binds
various steroids (oestradiol, progesterone) and non-steroidal anti-
androgens (hydroxyflutamide, nilutamide) with higher affinity
than the wild-type AR (Veldscholte et al, 1990). These substances,
in addition to androgens, induce transcriptional activity of the
LNCaP AR. LNCaP cells grow in response to androgenic, oestro-
genic and progestagenic steroids, hydroxyflutamide and nilu-
tamide (Schuurmans et al, 1988; Wilding et al, 1989). Conversely,
agonistic effects on LNCaP proliferation and AR activity were not
observed in the presence of another non-steroidal anti-androgen,
bicalutamide (Casodex) (Veldscholte et al, 1992). The prolifera-
tion of LNCaP cells is regulated by androgens in a biphasic
manner. It is enhanced by low concentrations of dihydrotestos-
terone (DHT), whereas higher androgen doses induce a progres-
sive decline in cellular proliferation. They induce expression of
prostate-specific genes, such as the prostate-specific antigen
(PSA) gene (Lee et al, 1995).
Androgen ablation therapy for advanced prostatic carcinoma
intends to block AR activation and function. Serum levels of
testicular androgens are thus lowered either by orchiectomy or by
analogues of luteinizing hormone-releasing hormone. These
compounds are applied together with an AR antagonist in order to
achieve a complete androgen blockade. The response to this
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Summary Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the
mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the
situation in patients who receive androgen ablation therapy. Androgen-sensitive LNCaP cells were kept in androgen-depleted medium for 87
passages. The new LNCaP cell subline established in this manner, LNCaP-abl, displayed a hypersensitive biphasic proliferative response to
androgen until passage 75. Maximal proliferation of LNCaP-abl cells was achieved at 0.001 nM of the synthetic androgen methyltrienolone
(R1881), whereas 0.01 nM of this compound induced the same effect in parental cells. At later passages (> 75), androgen exerted an
inhibitory effect on growth of LNCaP-abl cells. The non-steroidal anti-androgen bicalutamide stimulated proliferation of LNCaP-abl cells. AR
protein expression in LNCaP-abl cells increased approximately fourfold. The basal AR transcriptional activity was 30-fold higher in LNCaP-abl
than in LNCaP cells. R1881 stimulated reporter gene activity in LNCaP-abl cells even at 0.01 nM, whereas 0.1 nM of R1881 was needed for
induction of the same level of reporter gene activity in LNCaP cells. Bicalutamide that acts as a pure antagonist in parental LNCaP cells
showed agonistic effects on AR transactivation activity in LNCaP-abl cells and was not able to block the effects of androgen in these cells.
The non-steroidal AR blocker hydroxyflutamide exerted stimulatory effects on AR activity in both LNCaP and LNCaP-abl cells; however, the
induction of reporter gene activity by hydroxyflutamide was 2.4- to 4-fold higher in the LNCaP-abl subline. The changes in AR activity were
associated neither with a new alteration in AR cDNA sequence nor with amplification of the AR gene. Growth of LNCaP-abl xenografts in
nude mice was stimulated by bicalutamide and repressed by testosterone. In conclusion, our results show for the first time that the non-
steroidal anti-androgen bicalutamide acquires agonistic properties during long-term androgen ablation. These findings may have
repercussions on the natural course of prostate cancer with androgen deprivation and on strategies of therapeutic intervention.
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therapy is time-limited. Almost all tumours become refractory
after some time. Surprisingly, clinical benefit has been observed
following the withdrawal of anti-androgens in a subset of prostate
cancer patients with therapy-resistant disease (Scher and
Kolvenbag, 1997). This anti-androgen withdrawal phenomenon
may be in part attributed to mutant ARs detected in prostatic carci-
nomas but alternative mechanisms may also be considered. These
facts indicate that there may be clinically relevant changes in AR
expression and function during long-term androgen ablation. We
report here on characterization of a new LNCaP cell subline,
LNCaP-abl, which was established after 10 months propagation in
steroid-depleted medium. This characterization encompasses the
evaluation of in vitro and in vivo tumour growth, the expression
and activity of the AR and cytogenetic changes. Our study demon-
strates a hyperresponsiveness of the androgen-signalling pathway
in long-term androgen-deprived LNCaP cells.
MATERIALS AND METHODS
Materials
RPMI-1640 medium was purchased from HyClone (Logan, UT,
USA). Fetal calf serum (FCS) and penicillin–streptomycin were
from Biological Industries (Kibutz Beth Haemek, Israel). Cell
culture plasticware was from Falcon (Lincoln, NE, USA), Costar
(Cambridge, MA, USA) and Sarstedt (Nümbrecht, Germany). Non-
radioactive and 3H-labelled synthetic androgen methyltrienolone
(R1881, specific activity 86 Ci mmol–1) and acetyl-coenzyme A
(specific activity 57 mCi mmol–1) were purchased from New
England Nuclear (Dreieichenhain, Germany). Hydroxyflutamide
was from Essex Pharma (Munich, Germany) and bicalutamide from
Schering AG (Berlin, Germany). Chloramphenicol and unlabelled
acetyl-coenzyme A were supplied by Sigma (Deisenhofen,
Germany). The scintillation liquids Optiphase and Optiscint
‘Hisafe’ were from Pharmacia (Uppsala, Sweden). A commercial
methylthiotetrazole (MTT) assay was purchased from Biomedica
(Vienna, Austria). A luciferase assay kit was purchased from Bio
Orbit (Turku, Finland). Electroporation apparatus and cuvettes were
from Eurogentec (Brussels, Belgium). The softwares for karyo-
typing and comparative genomic hybridization (CGH) were from
Perceptive Scientific International (Chester, UK). Biotin- and
digoxigenin-labelled dUTPs were from Boehringer (Mannheim,
Germany). The Leitz Aristoplan epifluorescence microscope (Leica,
Vienna, Austria) was equipped with a cooled integrating black
and white charge-coupled device (CCD) Image Point camera
(Photometrics, Tucson, AZ, USA). A triple band-pass filter set was
from Chroma Technology (Brattleboro, VA, USA). The Polyvar 2
microscope from Reichert (Vienna, Austria) was equipped with a
video camera (Hamamatsu Photonics, Hamamatsu, Japan).
Cell culture
The LNCaP cell line was obtained at passage 21 from the
American Type Culture Collection (Bethesda, MD, USA). The
cells were routinely cultured in RPMI medium supplemented with
10% FCS and antibiotics at 37°C in an atmosphere of 5% carbon
dioxide in air. Medium was changed every 3–4 days and the cells
were passaged by trypsinization once a week with ratio 1:3.
Steroid removal was performed in two steps; initially, FCS was
incubated with dextran-coated charcoal at 4°C for 5 h. The char-
coal mixture was centrifuged at 3600 rpm for 20 min. Then the
supernatant was incubated with a fresh portion of dextran-coated
charcoal overnight, centrifuged, filtered through a 0.2 mm sterile
filter and stored at –20°C until use. Beginning with passage 25, we
have cultured LNCaP cells in 10% charcoal-stripped (CS) FCS
and antibiotics with medium change every 3–4 days and passage
once a week. The levels of testosterone, oestradiol and proges-
terone in CS FCS were determined by commercial radioim-
munoassays (RIAs). The testosterone RIA (sensitivity 0.14 nM)
was purchased from Diagnostic Products Corporation (Los
Angeles, CA, USA), RIA for determination of oestradiol (sensi-
tivity 0.05 nM) was from Serono (Roma, Italy) and the proges-
terone RIA (sensitivity 0.3 nM) was from Orion Diagnostica
(Espoo, Finland). Testosterone, oestradiol and progesterone were
not detected in CS FCS by these RIAs. The cells derived after 41
passages in steroid-free medium were named LNCaP-abl. Several
passages of these cells were characterized. Low passages of
LNCaP cells (25–36), which were not exposed to steroid depriva-
tion, served as controls.
Assessment of in vitro proliferation of LNCaP cells
Cell proliferation in the absence of any supplement was evaluated
by counting trypsinized cells with a haemocytometer. The cells were
counted after (a) culture of LNCaP cells in FCS and LNCaP-abl
cells in CS FCS, (b) culture of both cell lines in FCS and (c) culture
of both cell lines in CS FCC. Responsiveness of cell proliferation to
increasing concentrations of androgen and anti-androgens was
evaluated by means of the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. It was previously found that
MTT converting activity adequately reflects cell number in
androgen-treated LNCaP cells (Romijn et al, 1988). LNCaP cells
were seeded into 24-well plates at a density of 2 ´104per well. They
were grown in medium containing 10% CS FCS for 24 h. After this
period, the concentration of CS FCS was reduced to 5% and either
androgen or one of the non-steroidal anti-androgens (hydroxy-
flutamide, bicalutamide) was added. Proliferative response was
assessed after 72 h. The MTT assay was performed as recently
described by Cronauer et al (1996).
Ligand binding assay
About 3 ´ 106 cells were seeded into 75-cm2 flasks and incubated
for 48 h. Then they were taken to determine specific binding of
radioactively labelled methyltrienolone. The assay procedure was
essentially the same as that described previously (Culig et al,
1993a). In addition to determination of androgen binding, compe-
tition studies with bicalutamide were carried out and relative
binding affinity was calculated.
AR transcriptional activity
Activity of the AR was assessed in transactivation assays. The
reporter chloramphenicol acetyltransferase (CAT) gene, driven by
a promoter consisting of two androgen-response elements in front
of a TATA box (Culig et al, 1994), was introduced together with
the plasmid pGL3-control, which contains a luciferase gene driven
by the SV-40 promoter (Promega, Mannheim, Germany) into
LNCaP and LNCaP-abl cells by means of electroporation. Prior to
electroporation, the cells were grown in 75-cm2 flasks for 24 h.
They were washed in phosphate-buffered saline (PBS) and
trypsinized. Then 3.6 ´ 106 cells were resuspended in 400 ml of244 Z Culig et al
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PBS containing 10% CS FCS and mixed with 60 mg of the reporter
plasmid and 40 mg of the control plasmid. This suspension was
transferred into 4-mm cuvettes and electroporated. The parameters
were 650 V, 25 mF and 99 Ohm for pulse 1 and 220 V, 1050 mF
and 201 Ohm for pulse 2. Immediately afterwards, the cells were
resuspended in medium with 10% CS FCS and seeded on 24-well
plates. Hormones and/or AR antagonists were supplemented 24 h
after electroporation in the presence or absence of serum and the
cells were harvested after incubation for another 24 h. CAT assay
was performed in cell extracts as described previously (Culig et al,
1994). The results of reporter gene assays were normalized
according to protein levels and transfection efficacy which was
determined by the Bio Orbit luciferase assay. The luciferase assay
was performed according to the manufacturer’s instructions. To
test whether serum has any effect on the expression of the
luciferase control plasmid, both LNCaP sublines were transfected
with the pGL3-control plasmid and treated with 10% CS FCS for
24 h. Afterwards, luciferase activity was determined. To confirm
that reporter gene activity measured in CAT assays accurately
reflects functional activity of the AR, LNCaP and LNCaP-abl
cells were transfected with a control reporter gene plasmid lacking
the androgen-response elements (TATA-CAT) and incubated in
the absence or presence of androgen before CAT assay was
performed.
Determination of prostate-specific antigen mRNA levels
by semiquantitative RT-PCR
LNCaP and LNCaP-abl cells were cultured in medium supple-
mented with 5% CS FCS in the absence or presence of androgen
for 24 h. RNA was extracted according to the protocol described
previously (Culig et al, 1993b). A PSA cDNA fragment and a
cDNA fragment of the housekeeping gene b2-microglobulin were
amplified in a duplex PCR. Amplification was started with PSA
primers alone for 3 cycles. Thereafter, b2-microglobulin primers
were added and the amplification was continued for another 20
cycles. The following PCR programme was used: a precycle of 15
min at 95°C followed by 23 cycles of 50 s at 94°C, 1 min at 56°C,
30 s at 72°C and a postcycle of 2 min at 73°C. The primers used
for PSA detection were PSA 418/21 sense, 5¢-GGC AGG TGC
TTG TAG CCT CTC-3¢ (fluorescence-labelled); and 939/21 anti-
sense, CAC CCG AGC AGG TGC TTT TGC-3¢. The primers used
for the amplification of b2-microglobulin were sense, 5¢-ATG
CCT GCC GTG TGA ACC ATG T-3¢; and antisense, 5¢-AGA
GCT ACC TGT GGA GCA ACC T-3¢ (fluorescence-labelled).
The fragments were separated by capillary gel electrophoresis on
an ABI 310 Genetic Analyser (ABI, Foster City, CA, USA) and
the fluorescence intensities of the fragments were measured using
the ABI Prism Genescan Software. A PSA/b2-microglobulin ratio
was calculated.
Sequence analysis of AR cDNA fragments
Isolation of RNA from LNCaP and LNCaP-abl cells, cDNA
synthesis, amplification of AR cDNA fragments and sequencing
were performed as described previously (Culig et al, 1993b).
Cytogenetic analysis
Metaphase spreads were prepared from subconfluent cell mono-
layers after 1 or 2 days in culture. The cells in log phase were
microscopically checked for good mitotic index and harvested
by colcemid and trypsin treatment using standard methods.
Metaphase chromosomes were routinely analysed by trypsin-
Giemsa (GTG) and quinacrine (QFQ) banding. GTG- and QFQ-
banded chromosomes were recorded, karyotyped and processed by
MacKtype 5.1 software on a Polyvar 2 microscope.
CGH analysis
For CGH, metaphase chromosome preparation, DNA isolation and
labelling, hybridization and signal detection were performed essen-
tially as described previously (Kallioniemi et al, 1994). Briefly, test
DNA was isolated from cultured LNCaP and LNCaP-abl cells and
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Figure 1 Proliferative response of LNCaP and LNCaP-abl cells following androgen or bicalutamide treatment. Two ´ 104 cells were seeded into 24-well plates
and grown in the presence of indicated concentrations of R1881 or bicalutamide for 72 h. Proliferation was assessed by means of the MTT assay. Results are
expressed in relation to LNCaP cells stimulated by 0.01 nM of R1881 (=100%). (A) The effects of R1881 on LNCaP and LNCaP-abl cells (passages 56 and 75).
Points, mean values of three experiments; bars, s.d. (B) The effects of bicalutamide (Bic) on LNCaP (white bar) and LNCaP-abl cells (passage 68) (black bar)control DNA was prepared from blood of a healthy male. DNAs
were labelled with biotin-16-dUTP and digoxigenin-11-dUTP,
respectively, following standard nick translation protocols (Langer
et al, 1981). A 1:1 probe mixture (400–600 ng) was hybridized in
combination with unlabelled human Cot-1 DNA to normal male
metaphase spreads. Biotin- and digoxigenin-labelled probes were
visualized via fluorescein isothiocyanate (FITC) and tetrarho-
damine isothiocyanate (TRITC) respectively. Chromosomes were
identified on the basis of inverted grey level diamino-2-phenolidol
(DAPI) banding. CGH results were evaluated using a digital image
analysis system. Three single-colour images were recorded and
processed by the MacProbe 3.3 software on the Leitz Aristoplan
epifluorescence microscope. The microscope was equipped with a
cooled integrating black and white CCD camera and a triple band-
pass filter set in combination with single band-pass excitation
filters to sequentially excite DAPI, FITC and TRITC without any
registration shift between images. Green to red (tumour cell line to
normal) fluorescence intensity ratios along the length of all chro-
mosomes in the metaphase spreads were calculated, allowing an
objective assignment of DNA sequence copy number changes of
the tumour cell lines to chromosomal regions. After normalization
of absolute fluorescence intensities within each metaphase to an
average of 1.0, the results were plotted as green to red ratio profiles
for each human chromosome from pter to qter. Typically, 3–5 high
quality metaphases were analysed from each slide.
Assessment of growth of LNCaP cells in vivo
Six-week-old male athymic nude mice (NMRI-strain, Bommice,
Bomholdtgard, Denmark) were used in the in vivo experiments. The
animals were housed in a pathogen-free facility. Animal treatment
was according to Guidelines for the Welfare of Animals in
Experimental Neoplasia. Mice that should be transplanted with
LNCaP cells were supplemented with slow-release testosterone
pellets (12.5 mg, 90-day release; Innovative Research of America,
Sarasota, FL, USA). Prior to transplantation, LNCaP and LNCaP-
abl cells were expanded in vitro. Exponentially growing cells were
harvested and the cell pellet was resuspended in an appropriate
volume of RPMI-1640 medium. The cell suspension was mixed 1:1
with matrigel to inject 1.5 ´ 106 cells in 0.1 ml subcutaneously (s.c.)
into the left flank of each nude mouse. After the tumours had
reached a size of 25–35 mm2, either surgical castration under anaes-
thesia and testosterone pellet removal were performed or treatment
with the anti-androgen bicalutamide (50 mg kg–1 s.c. in benzyl
benzoate/castor oil, 3 ´ weekly, synthesized at Schering AG) was
started. Tumour size was measured weekly using a caliper (length ´
width of a tumour area in mm2). All tumours were of a very similar
shape. At the end of each experiment, tumours, prostate and seminal
vesicles were dissected and weighed.
RESULTS
Establishment of an androgen-hypersensitive LNCaP
subline
LNCaP cells obtained from the American Type Culture Collection
were grown for 10 months in medium supplemented with 10% CS
FCS. After 41 passages, the LNCaP-abl subline was established.
Morphology of these cells was different to that of parental cells.
Clusters of cells were observed in the subline generated after
androgen ablation rather than uniform monolayers.
Effects of long-term androgen ablation on proliferation
of LNCaP cells
The basal proliferation rate of both LNCaP sublines was evaluated
by determination of cell number after 3 days of growth. In the first
series of experiments, LNCaP cells were grown in medium supple-
mented with FCS and LNCaP-abl cells in medium containing CS
FCS. Until LNCaP-abl cells reached passage 61, their number was
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Figure 2 Specific androgen binding in LNCaP and LNCaP-abl cells
(passage 66). LNCaP cells were incubated in 75-cm2 flasks for 48 h. Then
the cells were harvested and incubated with increasing concentrations of 3H-
R1881 at room temperature for 90 min. Non-specific binding was measured
in the presence of a 200-fold molar excess of unlabelled R1881. After
incubation the cells were washed twice with ice-cold medium and specifically
bound radioactivity was determined
Figure 3 Assessment of AR transcriptional activity in LNCaP (white bar)
and LNCaP-abl (black bar) cells in the absence of androgen. The cells were
cotransfected with the androgen-responsive reporter plasmid ARE2TATA-CAT
and the plasmid pGL3-control containing a luciferase gene driven by the SV-
40 promoter. The basal CAT activity in LNCaP and LNCaP-abl cells was
measured in the presence or absence of serum. All CAT activities are
expressed in relation to the CAT activity induced by 1 nM of R1881 in LNCaP
cells (=100%, not shown); bars, s.d.246 Z Culig et al
British Journal of Cancer (1999) 81(2), 242–251 © 1999 Cancer Research Campaign
15–20% lower than that of LNCaP cells. Beginning with passage
61, the basal proliferation rate of LNCaP-abl cells was quite similar
to that of LNCaP cells. When LNCaP-abl cells were grown in FCS,
their number was more than 2 times lower than the number of
LNCaP cells. Finally, experiments in which both sublines were
cultured in CS FCS revealed that LNCaP cells grow up to 2 times
slower than LNCaP-abl cells in this medium. The effects of
increasing concentrations of androgen and the non-steroidal anti-
androgens hydroxyflutamide and bicalutamide on cellular prolifer-
ation were assessed by the MTT assay. The synthetic androgen
R1881 was added at concentrations ranging from 0.001 to 1 nM.
R1881 was used instead of DHT to minimize metabolic degrada-
tion of physiological androgen during incubation. Both the parental
cell line and LNCaP-abl cells showed a biphasic response after
incubation with androgen (Figure 1A). Maximal stimulation of the
parental cell line was observed at 0.01 nM of R1881, whereas a
tenfold lower concentration evoked maximal proliferative response
in androgen-ablated cells. LNCaP-abl cells at passage 75 and later
were inhibited by R1881 (Figure 1A). Hydroxyflutamide stimu-
lated proliferation of both LNCaP and LNCaP-abl cells in a similar
manner (data not shown). Surprisingly, bicalutamide, at concentra-
tions between 100 nM and 10 mM, stimulated proliferation of
LNCaP-abl cells (Figure 1B). Positive effects of bicalutamide on
growth of steroid-deprived LNCaP cells were observed in passages
in which very low concentrations of R1881 stimulated proliferation
as well as in those in which androgen inhibited cell growth.
AR expression during propagation in steroid-depleted
medium
AR protein level was estimated by ligand-binding assay with
radioactively labelled R1881. Maximum binding was determined
by means of Scatchard analysis. The number of binding sites in
LNCaP cells was comparable with that previously reported by
Kirschenbaum et al (1993) (1.2 vs 1.4 fmol mg–1 protein). Our
experiments revealed a gradual increase of AR during androgen
ablation. The maximal fourfold increase in androgen binding was
measured beginning with passage 66 (Figure 2) and remained
essentially unchanged until passage 87. There was no change in
AR binding affinity after long-term androgen deprivation.
Interestingly, relative binding affinity of AR for bicalutamide was
the same in LNCaP and LNCaP-abl cells (0.6). To investigate
whether AR up-regulation also occurs after short-term androgen
ablation, we cultured parental cells in medium with CS FCS for 4
days. Increased androgen binding was not measured in LNCaP
cells after short-term androgen withdrawal.
AR transcriptional activity
AR transcriptional activity was analysed by means of reporter
gene transactivation assays. Reporter gene activity was assayed in
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Figure 4 Cytogenetic changes of the LNCaP prostate cancer cell line
during in vitro propagation under steroid-free conditions. (A) Representative
QFQ-banded partial karyotype of the parental LNCaP cell line illustrating the
basic marker chromosomes M1 to M9. (B) Representative GTG-banded
partial karyotype of the LNCaP-abl subline (passage 75). Chromosomal
differences between karyotypes from LNCaP and LNCaP-abl were
duplication of the marker M1, formation of a new der(4) marker derived from
M8 and loss of the two Y-chromosomes (arrows)
Figure 5 CGH analysis in the parental LNCaP cell line (top) and in the
LNCaP-abl subline (passage 70) demonstrating genetic changes affecting
chromosomes 1, 2, X and Y (bottom). Average green to red fluorescence
intensity ratio profiles from 4 to 10 analysed chromosomes are shown from
pter to qter. Vertical lines represent green to red ratio values of 0, 0.5, 1, 1.5
and 2 (cut-off limits of losses and gains were taken at 0.75 and 1.25). The
mean ratio values in LNCaP cells indicate a loss of the 2p13-p21 region as
the only change whereas passage 70 of LNCaP-abl cells shows losses of
1p34-p36, 2p13-p21, Y and a gain of 1p22-qter. Idiograms are provided for
approximate visual reference of the breakpoints. Heterochromatic
chromosomal regions were excluded from the analysisextracts of LNCaP and LNCaP-abl cells which were transfected
with the ARE2 TATA-CAT construct and incubated with or without
R1881 for 24 h. Two types of experiments were performed. In the
first series of experiments, 5% CS FCS was present during incuba-
tion. In these experiments, parental LNCaP cells showed a very
low reporter gene activity in the absence of androgen. In contrast,
the basal CAT activity in androgen-ablated cells was approxi-
mately 30-fold higher in LNCaP-abl passages 63–66 than in
control cells (Figure 3). This increased basal CAT activity was also
measured up to passage 87 of LNCaP-abl cells. There was no
elevation of basal reporter gene activity in LNCaP cells which
were depleted of steroids for 4 days. Differences between control
cells and the LNCaP-abl subline were also notable after andro-
genic stimulation. Reporter gene activity was induced by tenfold
lower concentrations of androgen in LNCaP-abl than in LNCaP
cells (Table 1). In the second series of experiments, reporter gene
activity was measured in extracts of cells which were incubated in
the absence of androgen and serum (Figure 3). The basal CAT
activity was tenfold higher in LNCaP-abl than in LNCaP cells
even under these experimental conditions. CAT reporter gene
activities were normalized to luciferase activity of the pGL-3
control plasmid. In separate control experiments it was ensured
that the expression of the control luciferase gene is equal in
medium supplemented with FCS or CS FCS as well as in serum-
free medium. In experiments in which the reporter plasmid
TATA-CAT lacking the two androgen response elements was elec-
troporated, CAT activity was similar in LNCaP and in LNCaP-abl
cells. As expected, R1881 did not cause any stimulation of reporter
gene activity in cells that expressed this vector.
Next, we investigated the effects of the non-steroidal anti-
androgens hydroxyflutamide and bicalutamide on AR-mediated
reporter gene activity in androgen-ablated LNCaP cells. Agonistic
effects of hydroxyflutamide in parental LNCaP cells were
observed previously (Veldscholte et al, 1990, 1992). Stimulation
of AR activity by hydroxyflutamide was 2.4- to 4-fold higher in
LNCaP-abl cells than in LNCaP cells, thus confirming that these
cells adapted to an androgen-depleted environment by generating a
hyper-reactive AR (Table 1). Most interestingly, bicalutamide, a
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Figure 6 Growth characteristics of the LNCaP tumour in male nude mice.
LNCaP cells were transplanted s.c. into testosterone (T)-supplemented mice.
Two weeks later, nude mice bearing tumours were randomized and divided
into three groups (7–9 mice per group). The first group received no additional
treatment (control) and in the second group mice were castrated and
testosterone pellets were removed. Mice in the third group were treated with
bicalutamide (50 mg kg–1, 3 ´ weekly). The experiment was performed twice
and similar results were obtained
Figure 7 Growth characteristics of the LNCaP-abl tumour in male nude
mice. LNCaP-abl cells were transplanted s.c. into male nude mice. Two
weeks later, nude mice bearing tumours were randomized and divided into
five groups (7–10 mice per group). Treatment included castration,
bicalutamide (50 mg kg–1, 3 ´ weekly), castration plus bicalutamide (50 mg
kg–1, 3 ´ weekly) or testosterone supplementation. The experiment was
performed twice and similar results were obtained
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Table 1 Induction of CAT activity in LNCaP and LNCaP-abl cells transfected
with the androgen-inducible reporter plasmid ARE2TATA-CAT
Cell line (fold induction of CAT activity over
basal level ± s.d.)
Compound LNCaP LNCaP-abl
R1881 (0.01 nM) 1.2 ± 0.1 3.8 ± 0.2
R1881 (0.1 nM) 3.5 ± 0.5 14.4 ± 1.1
R1881 (1 nM) 33.2 ± 2.2 42 ± 1.5
OHF (100 nM) 2.5 ± 0.1 6.3 ± 0.8
OHF (1 mM) 3.8 ± 0.5 9.1 ± 1.2
OHF (10 mM) 4.5 ± 0.3 18.3 ± 2.2
R1881 (1 nM) + OHF (1 mM) 31.6 ± 2.2 35 ± 2.8
Bic (100 nM) 0.9 ± 0.1 1.8 ± 0.2
Bic (1 mM) 0.9 ± 0.2 2.2 ± 0.2
Bic (10 mM) 1.1 ± 0.1 2.8 ± 0.4
R1881 (1 nM) + Bic (1 mM) 3.2 ± 0.6 39.2 ± 5.2
OHF = hydroxyflutamide; Bic = bicalutamide.pure AR antagonist in parental cells, displayed positive effects on
reporter gene activity in LNCaP-abl cells. This compound inhib-
ited CAT activity induced by R1881 in LNCaP cells. In contrast,
the ability of bicalutamide to antagonize the effects of androgen on
reporter gene activity was greatly impaired in LNCaP-abl cells
generated after long-term androgen ablation (Table 1). This pattern
of AR activation was also observed in later passages of LNCaP-
abl cells (passages 67–87).
PSA mRNA expression
In order to investigate how long-term androgen ablation affects the
androgen-regulated PSA gene, LNCaP and LNCaP-abl cells were
treated with R1881 for 24 h and PSA mRNA was determined by
semiquantitative RT-PCR. Neither basal nor androgen-induced
PSA mRNA levels differed significantly between androgen-
ablated cells and controls. The mean PSA/b2-microglobulin ratio
was 0.2 in untreated LNCaP and 0.3 in LNCaP-abl cells. In
LNCaP cells treated with 1 nM of R1881 the mean PSA/b2-
microglobulin ratio was 1.7 compared with LNCaP-abl cells that
had a mean ratio of 1.3.
AR sequence and cytogenetic analysis
Sequence analysis of AR cDNA fragments revealed that the AR in
LNCaP-abl cells has the same sequence as the AR in LNCaP cells
(threonine at codon 877 is replaced with alanine) (Veldscholte et
al, 1990). The original cell line LNCaP and the LNCaP-abl subline
were analysed by both conventional karyotyping and CGH. Figure
4 summarizes chromosome findings of the two cell lines. Both the
parental cells and the LNCaP-abl subline had the same basic
karyotype. This was essentially a near tetraploid karyotype with
the consistent diploid markers M1 to M9 as reported by Gibas et al
(1984) and Konig et al (1989). Three additional chromosomal
changes compared to this basic karyotype were found in the
LNCaP-abl subline: (i) an additional copy of marker M1 was
present in LNCaP-abl cells; (ii) a new marker chromosome was
formed from one copy of M8 (4q+); and (iii) a partial or complete
loss of the Y-chromosome was observed (see also Table 2). Other
microscopical chromosome changes did not occur during in vitro
propagation.
Additionally, we have used CGH to identify clonal genetic
changes arising from in vitro selection of the LNCaP-abl subline.
CGH results from the two cell lines are shown in Figure 5. The
parental LNCaP cell line showed loss of the region 2p13–p21.
This change was also seen in the LNCaP-abl subline, whereas the
gain of 1p22.3–qter and the loss of the Y chromosome were found
only in the LNCaP-abl subline confirming in part conventional
cytogenetic findings. Moreover, loss of 1p34–p36 in LNCaP-abl
cells was found exclusively by CGH. None of passages of the
LNCaP-abl subline tested showed amplification sites, in particular
no amplification of the chromosomal region for the AR gene at
Xq11–13.
Growth of LNCaP sublines in nude mice
LNCaP cells were found to be tumorigenic in nude mice. Tumour
growth rate was improved when LNCaP cells were injected in
matrigel suspension and mice were supplemented with testos-
terone. A tumour take rate between 70 and 90% was achieved. In
contrast, we found no tumour growth of LNCaP-abl cells
(passages 73–87) in mice bearing testosterone pellets. However,
LNCaP-abl cells exerted tumour growth in nude mice without
androgen supplementation. Both cell lines showed similar growth
rates and 2 weeks after transplantation palpable tumours were
observed. After 3–4 weeks, a tumour size between 25 and 35 mm2
was reached.
Effects of anti-androgen therapy on in vivo growth of
LNCaP and LNCaP-abl tumours
Treatment with bicalutamide (50 mg kg–1, s.c.) resulted in an initial
inhibition of LNCaP tumour growth which was followed by a
relapse phase in which the tumours grew fast and reached the same
size as controls. Androgen ablation by castration was effective in
growth inhibition of the LNCaP xenotransplants and led to stabi-
lization of tumour growth (Figure 6) for the indicated time period.
This experiment was finished on day 65 when prostate and seminal
vesicle weights were determined. These parameters served for
assessment of the effect of treatment on non-malignant androgen-
sensitive tissues (Table 3). In a similar experiment, we found a
tumour relapse in castrated mice 70 days after tumour transplanta-
tion (data not shown). The LNCaP-abl xenografts grew well in
intact male mice without androgen supplementation (Figure 7).
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Table 2 Loss of the Y-chromosome evaluated by epifluorescence microscopy of QFQ-stained metaphases
Cell line Cells with XXYY Cells with XXY,-Y Cells with XX,-Y,-Y Total
(passage) (%) (%) (%) cells
LNCaP 27 (90) 3 (10) 0 (0) 30
LNCaP-abl (75) 0 (0) 21 (70) 9 (30) 30
LNCaP-abl (76) 1 (7.1) 8 (57.1) 5 (35.7) 14
Table 3 Prostate and seminal vesicle weight in tumour-bearing male nude
mice after androgen ablation, testosterone and anti-androgen treatment
respectively
Seminal vesicle s.d. Prostate s.d.
(relative weight in mg/100 g body weight)
LNCaP
Control (+testosterone) 821 203 190 32
Castration 101 11 48 14
Bicalutamide (+testosterone) 217 49 45 8
LNCaP-abl
Control 584 129 149 21
Castration 161 39 36 7
Bicalutamide 247 33 90 20
Castration + bicalutamide 100 24 30 3
Testosterone 964 151 227 66Bicalutamide and prostate cancer progression 249
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Bicalutamide (50 mg kg–1, s.c.) additionally stimulated tumour
growth. In castrated mice, tumours grew equally well as in intact
mice. However, tumours growing in castrated mice were even
more sensitive to the stimulatory effects of bicalutamide. In
contrast to original LNCaP cells, the implantation of testosterone
pellets in the LNCaP-abl tumour-bearing mice resulted in stabi-
lization of tumour size. As shown in Table 3, in both experiments
bicalutamide reduced prostate and seminal vesicle weight, demon-
strating the anti-androgenic effects of this drug on the proliferation
of non-malignant hormone-dependent tissues.
DISCUSSION
The major findings of this study are that after long-term androgen
ablation the AR becomes active in the absence of hormones and
serum and the pure AR blocker bicalutamide acquires agonistic
properties. This agonistic activity of bicalutamide was demonstrated
in cotransfection-transactivation assays and in experiments in which
tumour cell growth in vitro and in vivo was assessed. High AR
activity in the absence of measurable androgen in LNCaP-abl cells
suggested the development of a hypersensitive AR during propaga-
tion in steroid-depleted medium. One possible interpretation of our
data is that very low levels of steroid hormones which may be still
present in CS FCS stimulate AR activity in LNCaP-abl cells. We did
not detect any testosterone, oestradiol and progesterone in CS FCS
with RIAs. However, we cannot completely rule out the possibility
that concentrations of these hormones below assay detection limits
are present in CS FCS. We hypothesized that non-steroidal
substances present in serum are, at least in part, responsible for an
increased basal activity of the AR. Recent studies have shown that
growth factors, peptide hormones and substances which directly
activate protein kinases participate in AR signalling. Ligand-inde-
pendent activation of the AR by growth factors and protein kinase A
activators and synergistic effects of these activators and androgen
were reported (Culig et al, 1994, 1997a; Nazareth and Weigel,
1996). Furthermore, androgen-like effects of epidermal growth
factor and keratinocyte growth factor during sexual development
and AR-dependent stimulation of PSA secretion in explants of
prostate tissue by a cyclic adenosine monophosphate analogue were
described (Gupta et al, 1996; Nakhla et al, 1997; Thomson et al,
1997). We aimed to obtain more information on AR activation in
LNCaP-abl cells and reduced the influence of serum in subsequent
experiments as much as possible. Constitutive activity of the AR,
although diminished, was noted even under stringent experimental
conditions. The fact that in LNCaP-abl cells tenfold lower concen-
trations of R1881 than in original cells induced AR function
supports the concept of the development of receptor hypersensitivity
during androgen ablation in vitro. Experiments in which reporter
gene activity was measured after treatment with anti-androgens
provided additional evidence for AR hyperreactivity as an adapta-
tion to androgen depletion. Agonistic effects of hydroxyflutamide in
LNCaP cells were well-documented in the past (Veldscholte et al,
1990, 1992). Long-term androgen ablation apparently potentiates
agonism of hydroxyflutamide. In contrast to hydroxyflutamide, the
non-steroidal anti-androgen bicalutamide is an AR antagonist in
parental LNCaP cells but acts as an agonist in LNCaP-abl cells. The
induction of reporter gene activity was lower by bicalutamide than
by hydroxyflutamide; however, the induction by bicalutamide was
constantly observed at concentrations ranging between 100 nM and
10 mM. Although AR transcriptional activity in LNCaP-abl cells was
dramatically increased, there was a paradoxical finding that the
expression of the androgen-regulated PSA gene is unchanged. At
present, there is no explanation for this unexpected observation.
However, similar findings were reported for hypersensitive MCF-7
cells by Jeng et al (1998). Those cells also show an increased
oestrogen receptor activity but no elevation of the oestrogen-regu-
lated progesterone receptor and transforming growth factor-agenes.
Taken together, our results and those of Jeng et al suggest that not all
steroid-regulated genes are up-regulated after long-term steroid
depletion in tumour cells.
We speculated that either an alteration in the AR sequence or AR
gene amplification may be an underlying mechanism responsible
for the dramatic changes in the transcriptional activity of the
LNCaP-abl AR. However, the sequence of the AR in the LNCaP-abl
subline does not differ from the sequence of the AR in original cells.
Amplification of the AR gene was demonstrated in about 30% of
advanced prostate tumours (Visakorpi et al, 1995; Cher et al, 1996;
Koivisto et al, 1997). Our experiments revealed that this mechanism
is not operative in LNCaP-abl cells. Further studies on elucidation
of molecular mechanisms responsible for alterations in AR function
will focus on possible changes in interaction of the AR with
receptor-associated coactivator and co-repressor proteins and on
alterations in AR phosphorylation. Several nuclear receptor coacti-
vators were found to enhance AR-mediated transactivation (Voegel
et al, 1996; Yeh and Chang, 1996; Ikonen et al, 1997; Froesch et al,
1998). Miyamoto and colleagues reported that anti-androgens can
promote the interaction between the AR and its coactivator ARA70,
thus enhancing AR transcriptional activity (Miyamoto et al, 1997).
The hypothesis that changes in the expression and function of these
co-regulatory proteins occur during propagation in androgen-
depleted environment warrants further investigation.
The AR is expressed in early stage prostate cancer, in relapsed
tumours and in metastatic lesions from patients who failed
androgen ablation therapy (van der Kwast et al, 1991; Hobisch et
al, 1995, 1996; Taplin et al, 1995). Mutant ARs were discovered in
some primary tumours and, in higher percentage, in metastases
(reviewed by Culig et al, 1997b). These receptors are frequently
promiscuous responding to non-androgenic steroids and AR
antagonists and, most probably, play a role in prostate tumour
progression. Changes in AR activity described in the present
report, if not restricted to LNCaP cells, offer another possibility for
prostate tumour cells to escape ablation therapy. This fact may
additionally complicate the design of an appropriate endocrine
treatment for metastatic cancer of the prostate.
The cells generated in our laboratories and those characterized
by Kokontis et al (1994) share some common features. The
biphasic proliferative response shifted to lower androgen concen-
trations in LNCaP-abl, LNCaP-I (developed by Kokontis and asso-
ciates after 20–30 passages in androgen-depleted medium) and in
LNCaP-R cells (characterized after another 20–30 passages). AR
mRNA and protein increased during progression in cell culture in
LNCaP-I and LNCaP-R cells (Kokontis et al, 1994). Kokontis and
associates also reported on changes in AR activity in steroid-
depleted cells. Their observation that the induction of CAT activity
by R1881 is about sevenfold more efficient in androgen-ablated
than in original cells complies with our data. Finally, growth of
LNCaP-R cells in nude mice was inhibited by DHT, whereas finas-
teride, an inhibitor of the enzyme 5a-reductase, showed stimula-
tion of tumour growth (Umekita et al, 1996). While this manuscript
was in preparation, Kokontis et al (1998) reported that repression of
long-term androgen-ablated cells in vitro is associated with the
accumulation of the cyclin-dependent kinase inhibitor p27Kip1(1998). Although the LNCaP subline developed in our laboratories
and those described by Kokontis and associates (LNCaP-R1 and
-R2) are both repressed by androgen, they differ in their respon-
siveness to bicalutamide. This compound did not show a stimula-
tory effect on LNCaP-R proliferation (Kokontis et al, 1998).
Hence, phenotypical diversities after long-term androgen ablation
may occur. The anti-androgen bicalutamide was not tested in
LNCaP in vivo models so far. In our study, LNCaP tumours
regressed after castration, whereas bicalutamide treatment led to a
transient retardation of growth of LNCaP tumours in mice followed
by relapse. The size of prostate glands and seminal vesicles in bica-
lutamide-treated animals was reduced comparably to that in
castrated mice demonstrating a strong anti-androgenic effects of
this compound. Since bicalutamide stimulated proliferation of the
LNCaP-abl subline in cell culture, we questioned whether this anti-
androgen can also promote its growth in nude mice. We demon-
strated that bicalutamide strongly enhances growth of the
LNCaP-abl tumour in mice, whereas testosterone inhibits its prolif-
eration. Our findings clearly point out that long-term androgen
ablation favours selection of tumour cells in which anti-androgens
have agonistic activity thus underscoring the need to develop new
anti-androgens without partial agonistic activity.
Cytogenetic analysis of the parental human prostate cancer cell
line LNCaP used in this study revealed essentially the karyotype of
the cell line originally developed by Horoszewicz et al (1983) and
chromosomally characterized by Gibas et al (1984) and Konig et al
(1989). Thus, the basic karyotype of the original cell line was well
preserved. Duplication of the marker M1, interpreted as a der(1)
t(1;15) (p22.3; q24), was found also in other LNCaP sublines that
were established during in vitro propagation (Konig et al, 1989).
Data from those cell lines suggest that duplication of this marker is
rather a result of cytogenetic evolution during long-term in vitro
culture than a specific response of LNCaP cells to androgen-free
conditions. CGH analyses of the LNCaP cell line and androgen-
independent sublines derived after in vivo passages through athymic
mice were recently performed by Hyytinen et al (1997). In contrast
to the loss of the 2p13–p21 region which was the only change in
copy number in our study, these authors detected different changes
such as losses of chromosomal regions 1p34–p36, 2, 6cen–q23, 13q
and gains at 3q13–qter and 19p in the parental LNCaP cell line. This
might be the consequence of the use of different cell material since
the parental LNCaP cell line used by these authors was not obtained
from ATCC. It is remarkable that the loss of 1p34–p36 was also
found in our study, however, not in the parental LNCaP cell line but
in the androgen hypersensitive LNCaP-abl subline. Notably, none of
the consistent genetic changes which Hyytinen and associates found
in the in vivo selected sublines were detected in our in vitro selected
LNCaP-abl subline.
In summary, our results show for the first time that the anti-
androgen bicalutamide acquires agonistic properties during long-
term androgen ablation and that this phenomenon may be relevant
to prostate cancer progression. The findings reported in the present
study may have repercussions on the natural course of prostate
cancer with androgen deprivation and on strategies of therapeutic
intervention.
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